# Delcath Systems, Inc.: financial statements, quarterly

DCTH · Nasdaq · CIK 872912 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dcth.md) · [Financials](/companies/dcth/financials.md) · [Filings](/companies/dcth/filings.md) · [Insiders](/companies/dcth/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dcth/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.4](/filings/0001628280-24-046537.md) | [0.5 d](/filings/0001628280-25-010797.md) | [3.1](/filings/0001628280-25-023507.md) | [7.8](/filings/0001628280-25-038112.md) | [11.2](/filings/0001628280-25-048558.md) | [15.1 d](/filings/0001628280-26-012019.md) | [19.8](/filings/0001628280-26-031751.md) | [24.2](/filings/0001628280-26-053956.md) | [20.6](/filings/0001628280-25-048558.md) | [20.7 d](/filings/0001628280-26-012019.md) | [25.0](/filings/0001628280-26-031751.md) | [29.1](/filings/0001628280-26-053956.md) |
| Cost of revenue | $m | [0.1](/filings/0001628280-24-046537.md) | [0.2 d](/filings/0001628280-25-010797.md) | [0.9](/filings/0001628280-25-023507.md) | [1.5](/filings/0001628280-25-038112.md) | [1.6](/filings/0001628280-25-048558.md) | [2.1 d](/filings/0001628280-26-012019.md) | [2.8](/filings/0001628280-26-031751.md) | [3.3](/filings/0001628280-26-053956.md) | [2.6](/filings/0001628280-25-048558.md) | [3.0 d](/filings/0001628280-26-012019.md) | [3.7](/filings/0001628280-26-031751.md) | [3.0](/filings/0001628280-26-053956.md) |
| Gross profit | $m | [0.3](/filings/0001628280-24-046537.md) | [0.4 d](/filings/0001628280-25-010797.md) | [2.2](/filings/0001628280-25-023507.md) | [6.2](/filings/0001628280-25-038112.md) | [9.6](/filings/0001628280-25-048558.md) | [13.0 d](/filings/0001628280-26-012019.md) | [16.9](/filings/0001628280-26-031751.md) | [20.8](/filings/0001628280-26-053956.md) | [17.9](/filings/0001628280-25-048558.md) | [17.7 d](/filings/0001628280-26-012019.md) | [21.3](/filings/0001628280-26-031751.md) | [26.1](/filings/0001628280-26-053956.md) |
| Research and development | $m | [4.7](/filings/0001628280-24-046537.md) | [4.7 d](/filings/0001628280-25-010797.md) | [3.7](/filings/0001628280-25-023507.md) | [3.4](/filings/0001628280-25-038112.md) | [3.9](/filings/0001628280-25-048558.md) | [2.9 d](/filings/0001628280-26-012019.md) | [5.0](/filings/0001628280-26-031751.md) | [6.9](/filings/0001628280-26-053956.md) | [8.0](/filings/0001628280-25-048558.md) | [9.4 d](/filings/0001628280-26-012019.md) | [9.8](/filings/0001628280-26-031751.md) | [10.4](/filings/0001628280-26-053956.md) |
| Selling, general and administrative | $m | [6.2](/filings/0001628280-24-046537.md) | [7.0 d](/filings/0001628280-25-010797.md) | [8.8](/filings/0001628280-25-023507.md) | [6.8](/filings/0001628280-25-038112.md) | [7.0](/filings/0001628280-25-048558.md) | [7.0 d](/filings/0001628280-26-012019.md) | [11.3](/filings/0001628280-26-031751.md) | [11.4](/filings/0001628280-26-053956.md) | [10.3](/filings/0001628280-25-048558.md) | [10.5 d](/filings/0001628280-26-012019.md) | [13.1](/filings/0001628280-26-031751.md) | [13.4](/filings/0001628280-26-053956.md) |
| Operating income | $m | [(10.6)](/filings/0001628280-24-046537.md) | [(11.3) d](/filings/0001628280-25-010797.md) | [(10.3)](/filings/0001628280-25-023507.md) | [(3.9)](/filings/0001628280-25-038112.md) | [(1.3)](/filings/0001628280-25-048558.md) | [3.0 d](/filings/0001628280-26-012019.md) | [0.6](/filings/0001628280-26-031751.md) | [2.6](/filings/0001628280-26-053956.md) | [(0.4)](/filings/0001628280-25-048558.md) | [(2.2) d](/filings/0001628280-26-012019.md) | [(1.6)](/filings/0001628280-26-031751.md) | [2.4](/filings/0001628280-26-053956.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | [0.0](/filings/0001628280-25-023507.md) | [0.0](/filings/0001628280-25-038112.md) | [0.0](/filings/0001628280-25-048558.md) | [0.0 d](/filings/0001628280-26-012019.md) | [0.2](/filings/0001628280-26-031751.md) | [0.5](/filings/0001628280-26-053956.md) | [(0.5)](/filings/0001628280-25-048558.md) | [0.6 d](/filings/0001628280-26-012019.md) | [0.2](/filings/0001628280-26-031751.md) | [0.5](/filings/0001628280-26-053956.md) |
| Net income | $m | [(20.3)](/filings/0001628280-24-046537.md) | [(11.1) d](/filings/0001628280-25-010797.md) | [(11.1)](/filings/0001628280-25-048558.md) | [(13.7)](/filings/0001628280-25-048558.md) | [1.9](/filings/0001628280-25-048558.md) | [(3.4) d](/filings/0001628280-26-012019.md) | [1.1](/filings/0001628280-26-053956.md) | [2.7](/filings/0001628280-26-053956.md) | [0.8](/filings/0001628280-25-048558.md) | [(1.9) d](/filings/0001628280-26-012019.md) | [(1.1)](/filings/0001628280-26-053956.md) | [2.7](/filings/0001628280-26-053956.md) |
| Diluted EPS | $ per share | [(1.14)](/filings/0001628280-24-046537.md) | not reported | [(0.45)](/filings/0001628280-25-023507.md) | [(0.48)](/filings/0001628280-25-038112.md) | [0.06](/filings/0001628280-25-048558.md) | not reported | [0.03](/filings/0001628280-26-031751.md) | [0.07](/filings/0001628280-26-053956.md) | [0.02](/filings/0001628280-25-048558.md) | not reported | [(0.03)](/filings/0001628280-26-031751.md) | [0.07](/filings/0001628280-26-053956.md) |
| Basic EPS | $ per share | [(1.14)](/filings/0001628280-24-046537.md) | not reported | [(0.45)](/filings/0001628280-25-023507.md) | [(0.48)](/filings/0001628280-25-038112.md) | [0.06](/filings/0001628280-25-048558.md) | not reported | [0.03](/filings/0001628280-26-031751.md) | [0.08](/filings/0001628280-26-053956.md) | [0.02](/filings/0001628280-25-048558.md) | not reported | [(0.03)](/filings/0001628280-26-031751.md) | [0.07](/filings/0001628280-26-053956.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [40.5](/filings/0001628280-23-038618.md) | [12.6](/filings/0001628280-25-010797.md) | [11.8](/filings/0001628280-24-023087.md) | [14.8](/filings/0001628280-24-034769.md) | [8.3](/filings/0001628280-24-046537.md) | [32.4](/filings/0001628280-26-012019.md) | [12.8](/filings/0001628280-25-023507.md) | [34.4](/filings/0001628280-25-038112.md) | [41.8](/filings/0001628280-25-048558.md) | [43.5](/filings/0001628280-26-053956.md) | [41.3](/filings/0001628280-26-031751.md) | [47.5](/filings/0001628280-26-053956.md) |
| Current assets | $m | [46.1](/filings/0001628280-23-038618.md) | [37.2](/filings/0001628280-25-010797.md) | [33.6](/filings/0001628280-24-023087.md) | [31.4](/filings/0001628280-24-034769.md) | [28.9](/filings/0001628280-24-046537.md) | [73.8](/filings/0001628280-26-012019.md) | [84.3](/filings/0001628280-25-023507.md) | [113](/filings/0001628280-25-038112.md) | [121](/filings/0001628280-25-048558.md) | [120](/filings/0001628280-26-053956.md) | [120](/filings/0001628280-26-031751.md) | [131](/filings/0001628280-26-053956.md) |
| Total assets | $m | [47.6](/filings/0001628280-23-038618.md) | [38.6](/filings/0001628280-25-010797.md) | [36.1](/filings/0001628280-24-023087.md) | [33.9](/filings/0001628280-24-034769.md) | [31.7](/filings/0001628280-24-046537.md) | [76.6](/filings/0001628280-26-012019.md) | [87.3](/filings/0001628280-25-023507.md) | [117](/filings/0001628280-25-038112.md) | [124](/filings/0001628280-25-048558.md) | [124](/filings/0001628280-26-053956.md) | [125](/filings/0001628280-26-031751.md) | [137](/filings/0001628280-26-053956.md) |
| Current liabilities | $m | [14.0](/filings/0001628280-23-038618.md) | [16.4](/filings/0001628280-25-010797.md) | [13.3](/filings/0001628280-24-023087.md) | [12.3](/filings/0001628280-24-034769.md) | [21.6](/filings/0001628280-24-046537.md) | [6.1](/filings/0001628280-26-012019.md) | [5.3](/filings/0001628280-25-023507.md) | [10.4](/filings/0001628280-25-038112.md) | [8.0](/filings/0001628280-25-048558.md) | [11.0](/filings/0001628280-26-053956.md) | [10.7](/filings/0001628280-26-031751.md) | [13.3](/filings/0001628280-26-053956.md) |
| Total liabilities | $m | [22.9](/filings/0001628280-23-038618.md) | [22.8](/filings/0001628280-25-010797.md) | [21.5](/filings/0001628280-24-023087.md) | [29.7](/filings/0001628280-24-034769.md) | [23.1](/filings/0001628280-24-046537.md) | [7.8](/filings/0001628280-26-012019.md) | [7.1](/filings/0001628280-25-023507.md) | [11.9](/filings/0001628280-25-038112.md) | [9.4](/filings/0001628280-25-048558.md) | [12.4](/filings/0001628280-26-053956.md) | [12.1](/filings/0001628280-26-031751.md) | [15.9](/filings/0001628280-26-053956.md) |
| Long-term debt | $m | not reported | [10.2](/filings/0001628280-25-010797.md) | [7.4](/filings/0001628280-24-023087.md) | [4.5](/filings/0001628280-24-034769.md) | [2.0](/filings/0001628280-24-046537.md) | [0.0](/filings/0001628280-25-010797.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [24.7](/filings/0001628280-24-046537.md) | [15.8](/filings/0001628280-26-012019.md) | [14.6](/filings/0001628280-25-048558.md) | [4.2](/filings/0001628280-25-048558.md) | [8.6](/filings/0001628280-25-048558.md) | [68.7](/filings/0001628280-26-053956.md) | [80.2](/filings/0001628280-26-053956.md) | [105](/filings/0001628280-26-053956.md) | [115](/filings/0001628280-25-048558.md) | [111](/filings/0001628280-26-053956.md) | [113](/filings/0001628280-26-053956.md) | [121](/filings/0001628280-26-053956.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(9,161) d](/filings/0001628280-24-046537.md) | [(8,178) d](/filings/0001628280-25-010797.md) | [(9,584)](/filings/0001628280-25-023507.md) | [(4,451) d](/filings/0001628280-25-038112.md) | [(3,640) d](/filings/0001628280-25-048558.md) | [(1,006) d](/filings/0001628280-26-012019.md) | [2,203](/filings/0001628280-26-031751.md) | [7,293 d](/filings/0001628280-26-053956.md) | [4,772 d](/filings/0001628280-25-048558.md) | [8,248 d](/filings/0001628280-26-012019.md) | [857](/filings/0001628280-26-031751.md) | [5,712 d](/filings/0001628280-26-053956.md) |
| Capital expenditure | $k | [(1.0) d](/filings/0001628280-24-046537.md) | [19.0 d](/filings/0001628280-25-010797.md) | [13.0](/filings/0001628280-25-023507.md) | [101 d](/filings/0001628280-25-038112.md) | [216 d](/filings/0001628280-25-048558.md) | [229 d](/filings/0001628280-26-012019.md) | [140](/filings/0001628280-26-031751.md) | [398 d](/filings/0001628280-26-053956.md) | [459 d](/filings/0001628280-25-048558.md) | [550 d](/filings/0001628280-26-012019.md) | [570](/filings/0001628280-26-031751.md) | [503 d](/filings/0001628280-26-053956.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-031751.md) | [0.0 d](/filings/0001628280-26-053956.md) | not reported | not reported | [3,000](/filings/0001628280-26-031751.md) | [11.0 d](/filings/0001628280-26-053956.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.2](/filings/0001628280-23-038618.md) | [11.6](/filings/0001628280-24-023087.md) | [12.5](/filings/0001628280-24-034769.md) | [17.9](/filings/0001628280-24-046537.md) | [24.9](/filings/0001628280-25-023507.md) | [28.4](/filings/0001628280-25-038112.md) | [32.3](/filings/0001628280-25-048558.md) | [39.5](/filings/0001628280-26-031751.md) | [40.3](/filings/0001628280-26-053956.md) | [40.1](/filings/0001628280-25-048558.md) | [36.0](/filings/0001628280-26-031751.md) | [39.8](/filings/0001628280-26-053956.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 34,698,795 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-053956.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.